ATE107960T1 - Varianten von menschlichem gewebeplasminogenaktivator sowie verfahren zu deren herstellung. - Google Patents

Varianten von menschlichem gewebeplasminogenaktivator sowie verfahren zu deren herstellung.

Info

Publication number
ATE107960T1
ATE107960T1 AT89904712T AT89904712T ATE107960T1 AT E107960 T1 ATE107960 T1 AT E107960T1 AT 89904712 T AT89904712 T AT 89904712T AT 89904712 T AT89904712 T AT 89904712T AT E107960 T1 ATE107960 T1 AT E107960T1
Authority
AT
Austria
Prior art keywords
variants
methods
plasminogen activator
tissue plasminogen
production
Prior art date
Application number
AT89904712T
Other languages
English (en)
Inventor
Stephen P Anderson
Deborah L Higgins
Adair J Hotchkiss
Cara B Marks
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22620139&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE107960(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE107960T1 publication Critical patent/ATE107960T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Artificial Filaments (AREA)
  • Inorganic Fibers (AREA)
AT89904712T 1988-03-21 1989-03-06 Varianten von menschlichem gewebeplasminogenaktivator sowie verfahren zu deren herstellung. ATE107960T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/170,510 US5094953A (en) 1988-03-21 1988-03-21 Human tissue plasminogen activator variants

Publications (1)

Publication Number Publication Date
ATE107960T1 true ATE107960T1 (de) 1994-07-15

Family

ID=22620139

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89904712T ATE107960T1 (de) 1988-03-21 1989-03-06 Varianten von menschlichem gewebeplasminogenaktivator sowie verfahren zu deren herstellung.

Country Status (13)

Country Link
US (4) US5094953A (de)
EP (1) EP0401303B2 (de)
JP (2) JP2605155B2 (de)
AT (1) ATE107960T1 (de)
AU (1) AU635892B2 (de)
CA (1) CA1341612C (de)
DE (1) DE68916532T3 (de)
DK (1) DK175776B1 (de)
ES (1) ES2018367A6 (de)
GR (1) GR1000387B (de)
IL (1) IL89500A (de)
NZ (1) NZ228401A (de)
WO (1) WO1989009266A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI831484L (fi) * 1982-05-05 1983-11-06 Genentech Inc Plasminogen aktivator foer maenskovaevnad
ZA833174B (en) * 1982-05-05 1984-08-29 Genentech Inc Human tissue plasminogen activator
US5714372A (en) * 1985-04-22 1998-02-03 Genentech, Inc. Tissue plasminogen activator variants
ATE125294T1 (de) * 1987-10-29 1995-08-15 Yamanouchi Pharma Co Ltd Polypeptid-verbindungen.
DE3923339A1 (de) * 1989-05-31 1990-12-06 Boehringer Mannheim Gmbh Gewebs-plasminogen-aktivator-derivat
US5242688A (en) * 1990-12-24 1993-09-07 Eli Lilly And Company Method of treating thromboembolic disorders by administration of diglycosylated t-pa variants
US5595736A (en) * 1991-04-22 1997-01-21 Eli Lilly And Company Compounds and methods for treatment of thromboembolic disorders
US5468505A (en) * 1992-02-28 1995-11-21 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
DE69528614T2 (de) * 1994-07-07 2003-06-18 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno, Delft Modifizierte Proenzyme als Substrate für proteolische Enzyme
US6136548A (en) * 1994-11-22 2000-10-24 Rutgers, The State University Of New Jersey Methods for identifying useful T-PA mutant derivatives for treatment of vascular hemorrhaging
US6461640B1 (en) 1995-12-08 2002-10-08 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
US20030113271A1 (en) * 1997-01-29 2003-06-19 University Technology Corporation Formulations for pulmonary delivery
AU729489B2 (en) * 1997-07-23 2001-02-01 Roche Diagnostics Gmbh Production of human mutated proteins in human cells by means of homologous recombination
US6136536A (en) * 1997-10-29 2000-10-24 Genetics Institute, Inc. Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
US6283300B1 (en) 1998-08-21 2001-09-04 Joseph B. Bielagus Feed distribution for low velocity air density separation
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
JP3880036B2 (ja) * 2001-05-11 2007-02-14 全国酪農業協同組合連合会 タンパク質の濃縮方法
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
NZ532074A (en) * 2001-11-06 2006-02-24 Maxim Pharm Inc Compositions for the treatment of infectious diseases
US20080057050A1 (en) * 2003-05-02 2008-03-06 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
DE10342518A1 (de) * 2003-09-12 2005-05-12 Paion Gmbh Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität
AR068914A1 (es) * 2007-10-18 2009-12-16 Paion Deutschland Gmbh Uso de un activador de plasminogeno para la preparacion de un medicamento para el tratamiento de apoplejia
WO2015023830A1 (en) 2013-08-14 2015-02-19 Stc.Unm Treatment and prevention of stroke and other neurological disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58574B1 (en) * 1985-04-22 1993-10-06 Genentech Inc Human tissue plasminogen activator mutants, methods and intermediates therefor, and compositions using such mutants
ATE74379T1 (de) * 1985-12-23 1992-04-15 Chiron Corp Peptidplasminogenaktivatoren.
JP2527454B2 (ja) * 1986-01-31 1996-08-21 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド 新しい血栓溶解タンパク質
EP0234051B1 (de) * 1986-02-17 1991-12-11 Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis Gewebeplasminogen-Aktivator-Mutant, dafür kodierende rekombinante genetische Information und Verfahren zur Herstellung dieser Mutanten, deren Verwendung und pharmazeutische Zusammensetzungen
PT84588B (en) * 1986-04-02 1989-05-09 Beecham Group Plc Process for preparing a fibrinolytic enzyme
SE8702562L (sv) * 1987-06-18 1988-12-19 Kabigen Ab Nya fibrinolytiska enzymer
US4935237A (en) * 1988-03-21 1990-06-19 Genentech, Inc. Processes for the preparation of t-PA mutants
IL87276A (en) * 1987-08-03 1995-07-31 Fujisawa Pharmaceutical Co Analog of tissue plasminogen activator comprising only the kringle 2 and protease domain dna encoding the same processes for the preparation thereof and pharmaceutical compositions containing the same
EP0386240B1 (de) * 1987-10-29 1995-07-19 Yamanouchi Pharmaceutical Co. Ltd. Polypeptid-verbindungen
DE3937589C2 (de) * 1989-11-10 2001-12-13 Laing Oliver Zirkulationsgerät mit Widerstandsheizung

Also Published As

Publication number Publication date
IL89500A (en) 1998-09-24
AU635892B2 (en) 1993-04-08
DE68916532T3 (de) 2000-02-03
EP0401303A1 (de) 1990-12-12
DK175776B1 (da) 2005-02-14
ES2018367A6 (es) 1991-04-01
JP2605155B2 (ja) 1997-04-30
JPH09168387A (ja) 1997-06-30
DK227390A (da) 1990-09-20
EP0401303B2 (de) 1999-11-03
US5770425A (en) 1998-06-23
WO1989009266A1 (en) 1989-10-05
AU3414889A (en) 1989-10-16
IL89500A0 (en) 1989-09-10
CA1341612C (en) 2011-04-12
DE68916532D1 (de) 1994-08-04
DK227390D0 (da) 1990-09-20
US5366886A (en) 1994-11-22
GR890100164A (en) 1990-01-19
JPH03503363A (ja) 1991-08-01
EP0401303B1 (de) 1994-06-29
DE68916532T2 (de) 1995-01-12
NZ228401A (en) 1991-09-25
GR1000387B (el) 1992-06-30
US5314818A (en) 1994-05-24
US5094953A (en) 1992-03-10

Similar Documents

Publication Publication Date Title
ATE107960T1 (de) Varianten von menschlichem gewebeplasminogenaktivator sowie verfahren zu deren herstellung.
DE69921102D1 (de) Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen
DK0600866T3 (da) Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler
DE68929551D1 (de) Menschliche DNase
AU6701890A (en) Process for the production of biologically active protein
DE69435096D1 (de) Zusammensetzung zur in vivo erzeugung von therapeutischen produkten
DE3680368D1 (de) Biologisch aktive fragmente von humanem antihaemophiliefaktor, methode zu ihrer herstellung und pharmazeutische praeparate.
PT786257E (pt) Variantes de glicosilacao do activador de plasminogenio tissular com propriedades terapeuticas meloradas
DK0430200T3 (da) Polypeptidholdigt lægemiddel til subkutan eller intramuskulær applikation
IE960853L (en) Vascular anticoagulant proteins
DK431988D0 (da) Protein og dna til kodning deraf
DE3682891D1 (de) Gewebeplasminogen-aktivator-mutant, dafuer kodierende rekombinante genetische information und verfahren zur herstellung dieser mutanten, deren verwendung und pharmazeutische zusammensetzungen.
FI872526L (fi) Menetelmä biologisesti aktiivisen plasminogeeniaktivaattorin tuottamiseksi
IS2819B (is) Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra
DE69120287D1 (en) Aminosulfonylharnstoff-acat-inhibitoren
AU3744889A (en) Variants of plasminogen activators and processes for their production
DK167021C (da) Substituerede thiacykloalkene oe3,2-baapyridiner, fremgangsmaade til fremstilling deraf og praeparater indeholdende disse
EP0339505A3 (de) Monoklonale Antikörper gegen Gewebe-Plasminogen-Aktivator (t-PA), die sein funktionales Halbleben verlängern
FI102970B (fi) Menetelmä ihmisen kudostyyppisen plasminogeeniaktivaattorimuunnelman v almistamiseksi
ES2033295T3 (es) Un metodo para preparar un activador de plasminogeno.
ES8801624A1 (es) Procedimiento para preparar disulfuros heterociclicos
WO1992002612A3 (en) Tissue plasminogen activator variants with decreased clearance
HU912740D0 (en) Solubilisation of tissue plasminogene activator (t-pa)
DK421888A (da) Aeantifungale fermenteringsprodukter, fremgangsmaade til fremstilling deraf og praeparater indeholdende disseae
ATE49964T1 (de) Benzodioxepane, verfahren zur herstellung und verwendung als heilmittel.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time